247 related articles for article (PubMed ID: 11138845)
1. CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Waldmeier PC; Spooren WP; Hengerer B
Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):526-37. PubMed ID: 11138845
[TBL] [Abstract][Full Text] [Related]
2. Neurorescuing effects of the GAPDH ligand CGP 3466B.
Waldmeier PC; Boulton AA; Cools AR; Kato AC; Tatton WG
J Neural Transm Suppl; 2000; (60):197-214. PubMed ID: 11205140
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
Andringa G; van Oosten RV; Unger W; Hafmans TG; Veening J; Stoof JC; Cools AR
Eur J Neurosci; 2000 Aug; 12(8):3033-43. PubMed ID: 10971644
[TBL] [Abstract][Full Text] [Related]
4. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey.
Andringa G; Cools AR
J Neural Transm Suppl; 2000; (60):215-25. PubMed ID: 11205142
[TBL] [Abstract][Full Text] [Related]
5. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
6. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
Vaglini F; Pardini C; Cavalletti M; Maggio R; Corsini GU
Brain Res; 1996 Nov; 741(1-2):68-74. PubMed ID: 9001706
[TBL] [Abstract][Full Text] [Related]
7. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
8. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion.
Cutillas B; Ambrosio S; Unzeta M
Neurosci Lett; 2002 Aug; 329(2):165-8. PubMed ID: 12165403
[TBL] [Abstract][Full Text] [Related]
10. Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
Nam MH; Park M; Park H; Kim Y; Yoon S; Sawant VS; Choi JW; Park JH; Park KD; Min SJ; Lee CJ; Choo H
ACS Chem Neurosci; 2017 Jul; 8(7):1519-1529. PubMed ID: 28332824
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
12. CGP 3466 increases survival of cultured fetal dopaminergic neurons.
Matarredona ER; Meyer M; Seiler RW; Widmer HR
Restor Neurol Neurosci; 2003; 21(1-2):29-37. PubMed ID: 12808200
[TBL] [Abstract][Full Text] [Related]
13. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
[TBL] [Abstract][Full Text] [Related]
14. Rescue of dying neurons by (R)-deprenyl in the MPTP-mouse model of Parkinson's disease does not include restoration of neostriatal dopamine.
Steyn SJ; Castagnoli K; Castagnoli N
Ann N Y Acad Sci; 2001 Jun; 939():330-9. PubMed ID: 11462789
[TBL] [Abstract][Full Text] [Related]
15. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.
Visanji NP; Orsi A; Johnston TH; Howson PA; Dixon K; Callizot N; Brotchie JM; Rees DD
FASEB J; 2008 Jul; 22(7):2488-97. PubMed ID: 18364399
[TBL] [Abstract][Full Text] [Related]
16. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
19. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
[TBL] [Abstract][Full Text] [Related]
20. The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures.
Michel PP; Agid Y
Brain Res; 1992 Dec; 597(2):233-40. PubMed ID: 1361874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
